Table 2.
Ranking of immunochemotherapy regimens by PFS.
| Regimen | SUCRA | PbBT | PoRa [95% BCI] |
|---|---|---|---|
| G-Benda-G | 0.97 | 72% | 1 [1–3] |
| R-Benda-R4 | 0.88 | 25% | 2 [1–5] |
| R-Benda-R | 0.81 | 3% | 3 [1–4] |
| G-CHOP-G | 0.66 | 0% | 4 [2–7] |
| R-CHOP-R | 0.51 | 0% | 6 [4–8] |
| R-Len-R | 0.5 | 0% | 6 [3–10] |
| R-Benda | 0.48 | 0% | 6 [4–8] |
| G-CVP-G | 0.28 | 0% | 8 [5–11] |
| R-CHOP | 0.19 | 0% | 9 [7–11] |
| R-CVP-R | 0.16 | 0% | 9 [7–11] |
| R-CVP | 0.05 | 0% | 11 [8–11] |
SUCRA surface under the cumulative ranking curve, PbBT probability of being the best treatment, PoRa posterior ranking, BCI Bayesian credible interval.